“There is an increased risk with various types of infections in wounds following surgical and or traumatic injury,” says Gellman. The rise in post injury and surgical wounds and infections has influenced the number of readmissions to hospitals. The EnerAid™ active bandage system, Garwood’s advanced bandage system, aims to decrease patient visits by allowing clinical care at hospital and home. The bandage system facilitates the patient’s ability to move around while maintaining the sterile environment at site of wound and decreases the discomfort of the healing process. The EnerAid™ active bandage system uses a smart battery management system to stimulate the wound by passing controlled electric current at the site of wound.
“Our patented technologies have yielded proven results in accelerating the recovery process through the use of biocompatible materials with novel and advanced features,” attests Gellman. In addition, these technologies are designed to be patient-specific, thereby reducing the need for clinical intervention once the treatment parameters are set.
While the advanced wound care market holds a significant value in the healthcare industry, most large enterprises consider R&D to be a significant drain of resources and funds.
Our patented technologies have yielded proven results in accelerating the recovery process through the use of biocompatible materials with novel and advanced features
In contrast to this trend, Garwood follows a lean model that makes it possible to move faster in the R&D space by remaining laser-focused on their core competencies. Additionally, Garwood’s collaboration with clinical luminaries and government agencies ensures that the company is abreast with the market demands and evolving compliance regulations. According to Gellman, the approach makes it possible for Garwood to maintain a swift commercialization schedule. “Our mantra is focused on leveraging a strong patent portfolio, utilizing a swift and concise regulatory strategy to maintain our commercialization schedule,” says Gellman. In addition, Garwood’s strategy is to work with entities that can provide medical and healthcare students with comprehensive wound care education and create an awareness of the advanced EnerAid™ active bandage system.
Gellman believes that increasing the accountability of care organizations will challenge the previous reimbursement models presented by the healthcare system since the new reimbursement models emphasize quality values and outcomes. Excelling through an R&D team that is handpicked by Gellman himself, Garwood is driven by the belief that the success of a biotechnology firm is influenced by the collective vision of the team. While providing training to students from diverse universities, Garwood hires the crème de la crème among those to be part of its permanent team.
Moving ahead, Garwood can be expected to venture into roads untaken, with the aim of providing better post-operation recovery experiences to patients and ultimately increasing positive clinical outcomes. While the EnerAid™ active bandage system delivers patient-specific care, Garwood’s strategy has a technological twist as well. In the future, the bandages will be able to record bio-informatics data required to treat patients with similar history and risk factors, resulting in better triaging. Additionally, the future generations of the EnerAid™ active bandage system will have the ability be monitored and controlled wirelessly adjusting the current flow germane to the stage of healing. Using their patented technology, Garwood is set to turn heads and raise eyebrows in the wound care market.